 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C25H26N4O4 |
| Molar mass | 446.507 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor[1] that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.[2][3]
Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies.
|
| |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antiplatelet drugs |
| ||||||||||||||
| Anticoagulants |
| ||||||||||||||
| Thrombolytic drugs/ fibrinolytics |
| ||||||||||||||
| Non-medicinal |
| ||||||||||||||
| |||||||||||||||
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
